Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with
                    PARP
                    inhibitors

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

Violeta Serra; Francesc Viñals

doi:10.15252/emmm.201911217

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

Violeta Serra & Francesc Viñals · 2020-05-13

Mitochondrial metabolism and the generation of reactive oxygen species (ROS) contribute to the acquisition of DNA mutations and genomic instability in cancer. How genomic instability influences the metabolic capacity of cancer cells is nevertheless poorly understood. Here, we show that homologous recombination-defective (HRD) cancers rely on oxidative metabolism to supply NAD

NCI NIH HHS

R01 CA149385

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

Links

Journal

Institutions

Authors

Funding